Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.68 |
| ▸ | TSHR | P16473 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.68 |
| ▸ | PGR | P06401 | 4/20 | 0.68 |
| ▸ | AR | P10275 | 4/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.68 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664622 | 1.00 | LMNA (0.75) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL27270127 | 0.89 | LMNA (0.75) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL22492928 | 0.89 | LMNA (0.73) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL7125292 | 0.88 | LMNA (0.78) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL7123715 | 0.88 | LMNA (0.78) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL16045649 | 0.88 | LMNA (0.75) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL11349032 | 0.87 | LMNA (0.81) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL25863374 | 0.86 | LMNA (0.77) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL25863379 | 0.86 | LMNA (0.77) | LMNACYP3A4TSHRMAPTNR3C1 | |
| SCHEMBL6445272 | 0.86 | LMNA (0.77) | LMNACYP3A4TSHRMAPTNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418920-A4 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS INC (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1418920-A1 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003011300-A1 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20030022875-A1 | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness | VIVUS INC. | 2003-01-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022875-A1 | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness | SHBG, FSHR, GNRHR | LMNA 4836/4885CYP3A4 316/4885TSHR 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.